FDA approves Eli Lilly Alzheimer’s drug

The Food and Drug Administration announced Tuesday the approval of a new Alzheimer’s drug from Eli Lilly, which has demonstrated moderately slow cognitive and memory decline in patients with the disease. The drug, donanemab, marketed under the label Kisunla, is a once-monthly monoclonal antibody infusion. The drug works by removing the excessive build-up of amyloid plaques in the brain, which are proteins thought to be the cause of thinking issues associated with Alzheimer’s disease. “Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer’s disease, who urgently need effective...